Ai Feedback
Exact(8)
Mean accumulated quality-adjusted life-years (QALYs) did not differ (1.10 vs 1.12; adjusted mean difference favouring infliximab treatment 0.01 (95% CI −0.07 to 0.08)).
Subgroup analysis shows a significant standardized mean difference favouring OROS methylphenidate over atomoxetine.
Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate 0.32 (95% CI 0.12-0.53 (Z = 3.05, p < 0.002).
Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate (SMD = 0.32, 95% CI 0.12-0.53 (Z = 3.05, p < 0.002).
Mean accumulated QALYs using the US EQ-5D preference set were 1.27 in the infliximab and 1.28 in the conventional treatment group (adjusted mean difference favouring infliximab treatment 0.01; 95% CI −0.05 to 0.06; table 2).
DPICS scores were combined using a random effects model and the combined data (see Figure 4) show a significant standardised mean difference favouring the intervention group of SMD -0.44 (95% CI: -0.66, -0.23).
Similar(52)
The increase in the haematocrit compared with the baseline was statistically significant for both groups and comparing the effects of the two groups the weighted mean difference favoured the heater probe (−2.90; 95% CI −5.22 to −0.58).
Random effects meta-analysis suggested a non-statistically significant (p = 0.69) weighted mean difference in favour of the e-LDs [N ~ −0.12, 0.29].
After 3 months, there was a significant mean difference in favour of the reablement group in the COPM performance score of 1.5 points (95 % CI: 0.3-2.8, p = 0.02) (Table 3).
For the intention to treat analysis, the mean difference in favour of surgery was 11.2 between the groups with adjustment for only the minimisation variables (model I) and this increased to 14.1 when we included the baseline score (model II).
At post-test the mean difference in favour of the intervention group was -0.37 scores (95% CI -0.08 to -0.67) and 18% fewer residents compared to the control group used antipsychotic drugs (95% CI -3 to -33%).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com